About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 253409, 19 pages
http://dx.doi.org/10.1155/2012/253409
Research Article

Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention

1The Centre of Evidence Based Medicine, Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, NO. 1 Huatuo Road, Shangjie University Town, Fuzhou 350108, China
2The Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China
3Pamir Communications, Daly City, CA 94015, USA

Received 18 August 2011; Accepted 6 December 2011

Academic Editor: Myeong Soo Lee

Copyright © 2012 Guo-Hua Zheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. S. Reddy, “Cardiovascular disease in non-western countries,” New England Journal of Medicine, vol. 350, no. 24, pp. 2438–2440, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Aboderin, A. Kalache, Y. Ben-Shlomo, et al., Life Course Perspectives on Coronary Heart Disease, Stroke and Diabetes, World Health Organization, Geneva, Switzerland, 2002.
  3. T. A. Gaziano, “Reducing the growing burden of cardiovascular disease in the developing world,” Health Affairs, vol. 26, no. 1, pp. 13–24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. E. D. Grech, “ABC of interventional cardiology: percutaneous coronary intervention. II: the procedure,” British Medical Journal, vol. 326, no. 7399, pp. 1137–1140, 2003. View at Scopus
  5. X. Ma, T. Wu, M. P. Robich et al., “Drug-eluting stents,” International Journal of Clinical and Experimental Medicine, vol. 3, no. 3, pp. 192–201, 2010. View at Scopus
  6. H. C. Lowe, S. N. Oesterle, and L. M. Khachigian, “Coronary in-stent restenosis: current status and future strategies,” Journal of the American College of Cardiology, vol. 39, no. 2, pp. 183–193, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. G. W. Stone, S. G. Ellis, D. A. Cox et al., “A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease,” New England Journal of Medicine, vol. 350, no. 3, pp. 221–231, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Aziz, J. L. Morris, and R. A. Perry, “Late stent thrombosis associated with coronary aneurysm formation after sirolimus-eluting stent implantation,” Journal of Invasive Cardiology, vol. 19, no. 4, pp. E96–E98, 2007. View at Scopus
  9. B. Lagerqvist, S. K. James, U. Stenestrand, J. Lindbäck, T. Nilsson, and L. Wallentin, “Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden,” New England Journal of Medicine, vol. 356, no. 10, pp. 1009–1019, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J. F. Lassen, “Long-term safety and efficacy of drug-eluting stents,” The Lancet, vol. 377, no. 9773, pp. 1213–1214, 2011. View at Publisher · View at Google Scholar
  11. H. L. Kim, K. W. Park, J. J. Kwak et al., “Stent-related cardiac events after non-cardiac surgery: drug-eluting stent vs. bare metal stent,” International Journal of Cardiology, vol. 123, no. 3, pp. 353–354, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Camenzind, “Treatment of in-stent restenosis—back to the future?” New England Journal of Medicine, vol. 355, no. 20, pp. 2149–2151, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. E. Pfisterer, B. Richartz, and S. Silber, “The BASKET-LATE study: basel stent cost-effectiveness trial—late thrombotic events trial,” Herz, vol. 31, no. 3, p. 259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. J. M. Ten Berg, H. W. Thijs Plokker, and F. W. A. Verheugt, “Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention,” Current Controlled Trials in Cardiovascular Medicine, vol. 2, no. 3, pp. 129–140, 2001. View at Scopus
  15. C. L. Grines, R. O. Bonow, D. E. Casey et al., “Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents,” Circulation, vol. 115, no. 6, pp. 813–818, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. Q.-J. Meng, J. Wang, and R. Wu, “Progress of traditional Chinese medicine intervention after Percutaneous coronary intervention,” China Journal of Chinese Materia Medica, vol. 33, no. 8, pp. 962–965, 2008.
  17. D. Ren, Y. Wu, J. Huang, and K. Wang, “Clinical study of Danshen Shuizi capsule in preventing restenosis after stent placement,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 25, pp. 1518–1520, 2010.
  18. W. H. Wang, H. Y. Zhao, and J. M. Lang, “Effect of Shenqi decoction on hs-CRP, sIL-2R and activation of T lymphocytes after percutaneous coronary intervention,” Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 8, pp. 413–415, 2010.
  19. X. Li, Z. Chen, G. S. Ma, et al., “Experimental study of preventive effect of tetramethylpyrazine-eluting stent on in-stent restenosis,” Journal of Southeast University, vol. 27, pp. 102–105, 2008.
  20. G. H. Tang, X. L. Tang, and G. H. Jiang, “Effect of perlolyrine and its analogues on platelet aggregation and experimental thrombosis,” Chinese Pharmacological Bulletin, vol. 17, no. 3, pp. 333–336, 2001. View at Scopus
  21. B. Wu, M. Liu, H. Liu et al., “Meta-analysis of traditional Chinese patent medicine for ischemic stroke,” Stroke, vol. 38, no. 6, pp. 1973–1979, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. W. Gong and Z. Chen, “Advancement of studies on Traditional Chinese medicine for restenosis after percutaneous coronary intervention,” Zhejiang Journal of Integrated Traditional and Western Medicine, vol. 13, pp. 328–331, 2003.
  23. W. F. Zhang and Y. Yang, “Traditional Chinese medicine treating and preventing restenosis after percutaneous coronary intervention,” Liaoning Journal of Traditional Chinese Medicine, vol. 32, pp. 84–85, 2005.
  24. Y. Ren, K. J. Chen, and X. M. Ruan, “Systematic review of randomized controlled trials on preventing and treating restenosis after percutaneous coronary intervention with Chinese medicine,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 28, no. 7, pp. 597–601, 2008. View at Scopus
  25. Chinese Society of Cardiology of Chinese Medical Association, “Editorial Board of Chinese Journal of Cardiology. Chinese Guidelines for percutaneous coronary intervention (2009),” Chinese Journal of Cardiology, vol. 37, pp. 4–25, 2009.
  26. J. P. Liu, M. Zhang, W. Y. Wang, and S. Grimsgaard, “Chinese herbal medicines for type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews, no. 3, article CD003642, 2004. View at Scopus
  27. J. Higgins and S. Green, “Assessing risk of bias in included studies,” in Cochrane Handbook for Systematic Reviews of Intervenions Volume Version 502: the Cochrane Collaboration, J. Higgins and S. Green, Eds., 2009.
  28. J. Lau, J. P. A. Ioannidis, and C. H. Schmid, “Quantitative synthesis in systematic reviews,” Annals of Internal Medicine, vol. 127, no. 9, pp. 820–826, 1997. View at Scopus
  29. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003. View at Scopus
  30. D. B. Petitti, “Statistical methods in meta-analysis,” in Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine, D. B. Petitti, Ed., pp. 90–114, Oxford University Press, New York, NY, USA, 1994.
  31. J. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2, The Cochrane Collaboration, 2009.
  32. X. Y. Cue, Q. Lin, Y. B. Nong et al., “Clinical study of lianxue shengji recipe on incidence of post-percutaneous coronary intervention restenosis and adverse cardiovascular events,” Modern Chinese Medicine, vol. 11, pp. 40–42, 2009.
  33. Q. Wang, Z. G. Yi, Y. Q. Shu et al., “Effect of guantong formula on hs-CRP after intracoronary bare stenting,” Journal of New Chinese Medicine, vol. 42, pp. 11–13, 2010.
  34. Z. Q. Qiao, M. Z. Zhang, H. Liu, K. L. Chen, and S. Li, “A randomized double-blinded placebo-controlled clinical study of Tongguan capsule improving cardiac functional parameter of patients after PCI,” Chinese Archives of Traditional Chinese Medicine, vol. 21, pp. 882–883, 2003.
  35. H. Y. Wang, T. N. Fang, F. Wu, J. Zhao, Y. M. Tan, and X. Z. Zhang, “Study on the effects on hemorheology of CHD patients by Tonifying qi and activating blood after percataneous coronary intervention,” Liaoning Journal of Traditional Chinese Medicine, vol. 36, pp. 397–398, 2009.
  36. X. Wang, Z. X. Lin, J. B. Ge, Y. He, L. Shen, and Z. J. Zhang, “The change of primary asthenia-secondary sthenia syndrome of coronary heart disease before and after stenting and therapical function of shuxin yin,” Chinese Journal of Information, vol. 9, pp. 13–15, 2002.
  37. K. J. Chen, D. Z. Shi, and H. Xu, “Multi-central randomized double-blinded controlled trial of Xiong shao capsule preventing restenosis of patients with coronary heart disease after percutaneous coronary intervention,” in Proceedings of the 6th National Congress on Blood Stasis Syndrome, pp. 23–28, Beijing, China, 2005.
  38. Y. He, X. Wang, Z. X. Lin, and J. B. Ge, “Effect of Shuxinyin combination therapies for restenosis after PCI,” Journal of Traditional Chinese Medicine, vol. 43, pp. 701–703, 2002.
  39. J. C. Song, G. M. Hang, Z. R. Ding, C. H. Zheng, and J. T. Jie, “Effects of shuxuetong on acute coronary syndrome patients after interventional therapy,” Shanxi Medical Journal, vol. 38, pp. 439–441, 2009.
  40. H. Xu, K. J. Chen, D. Z. Shi, and J. M. Mao, “Clinical study of xiongshao capsule in preventing restenosis after coronary interventional treatment,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 8, pp. 162–166, 2002.
  41. H. An, C. M. Mu, and X. S. Li, “Preventive effect of qi-supplementing and stasis-resolving prescription on restenosis of 60 patients with coronary heart disease after percutaneous coronary intervention,” Traditional Chinese Medicinal Research, vol. 22, pp. 26–27, 2009.
  42. Z. M. Bao, S. L. Wu, X. J. Shi et al., “The clinical observation on puerarin preventing restenosis after percutaneous coronary intervention in patients with acute coronary syndrone,” Journal of Emergency in Traditional Chinese Medicne, vol. 14, pp. 613–614, 2005.
  43. G. H. Chen and K. Y. Song, “A sustained administration of tripterygium glycosides to reduce restenosis after coronary stenting,” ACTA Medicinae Sinica, vol. 18, pp. 507–509, 2005.
  44. H. Chen, Z. A. Yi, S. Y. Yi, W. P. Hu, and F. Yi, “Efficacy of danshen injection after coronary stent implantation,” Shanghai Medical and Pharmaceutical Journal, vol. 26, pp. 174–176, 2005.
  45. F. Y. Chu, J. Wang, X. W. Sun et al., “A randomized double-blinded controlled trial of Xuefu Zhuyu Capsule on short-term quality of life in unstable anginal patients with blood-stasis syndrome after percutaneous coronary intervention,” Journal of Chinese Integrative Medicine, vol. 7, no. 8, pp. 729–735, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. X. Y. Cui, Y. Wu, Y. B. Nong, et al., “Effect of liangxue shengji recipe on incidence of post-percutaneous coronary intervention restenosis and adverse cardiovascular events,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 30, pp. 30–32, 2010.
  47. D. W. Dan, Clinical study on wenyang huoxue decoction to impact yang deficiency and blood stasis of post percutaneous coronary intervention patients, M.S. thesis, Guangzhou University of Chinese Medicine, Guangzhou, China, 2009.
  48. S. Y. Ding, P. Wan, L. X. Guan, X. Y. Yang, S. Y. He, and Y. Q. Cui, “Investigation of the effect of xuezhikang on the prevention for the restenosis after PCI with non-drug eluting stent in patients with coronary heart disease,” China Practical Medicine, vol. 2, pp. 12–14, 2007.
  49. Q. M. Feng, Y. R. Dong, and Z. F. Yang, “Effect of tongxinfang on coronary collateral formation and stent-restenosis in patients with coronary artery disease after stenting,” China Journal of Rehabilitation and Practice, vol. 12, pp. 152–153, 2006.
  50. G. S. Fu, “Clinical observation of compound Danshen drop pill preventing restenosis of patients with coronary heart disease after stenting operation (Part 1),” China Medical Herald, vol. 6, pp. 68–69, 2009.
  51. X. Gu, S. Z. Shang, J. L. Gao et al., “Jiawei xuefu zhuyu drop treating and preventing restenosis after stenting intervention,” Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 5, pp. 1042–1043, 2007.
  52. L. E. Guo, X. H. Chen, and R. S. Zhang, “Far prognostic clinical study on patients of medicinal bracket operation of coronary artery with salvia tablet,” Journal of Zhejiang University of Traditional Chinese Medicine, vol. 33, pp. 327–328, 2009.
  53. Y. J. Han, Clinical study on intervention of Xuesaitong soft capsule on coronary heart disease patient after PCI, M.S. thesis, Guangzhou University of Chinese Medicine, Guangzhou, China, 2008.
  54. J. S. He, Q. Wang, Z. G. Yi et al., “Effect of guantong formula on restenosis after intracoronary bare stenting,” Journal of Traditional Chinese Medicine, vol. 51, pp. 423–425, 2010.
  55. Y. Kai, H. L. Liu, and Y. M. Zhao, “Clinical research of preventing post-PCI restenosis with tongxinluo capsule and complex dripping pill danshen,” Chinese Journal of Practical Medicine, vol. 35, pp. 24–26, 2008.
  56. A. H. Li, K. Z. Gong, J. F. Yan, X. Sun, Y. Feng, and Z. Zhang, “Effect of shuxuetong in preventing restenosis after intracoronary stenting,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 24, no. 10, pp. 879–881, 2004. View at Scopus
  57. G. H. Li, G. S. Fu, and X. Q. Zhou, “Clinical observation of compound danshen drop pill preventing restenosis of patients with coronary heart disease after stenting operation (Part 2),” Modern Journal of Integrated Traditional Chinese and Western Medicine, vol. 19, pp. 920–921, 2010.
  58. J. Li, W. H. Zhang, M. Z. Zhang, and X. Z. Lin, “Clinical observation of Tongguan capsule treating restenosis of 26 patients with syndrome of deficiency of vital energy and blood stasis after PCI,” New Journal of Traditional Chinese Medicine, vol. 37, pp. 33–35, 2005.
  59. L. T. Li and K. Y. Song, “Effect of sini tang on restenosis after cytoskeletal operation on coronary artery,” Journal of Changchun University of Traditional Chinese Medicine, vol. 22, pp. 8–9, 2006.
  60. Q. H. Li, X. B. Li, Q. Y. Li et al., “Clinical study on tongmaiyixin concentrated pill to prevent restenosis after intracoronary stenting,” China Medicine Herald, vol. 5, pp. 6–8, 2008.
  61. X. B. Li, “Observation of Xingmai futong decoction for prevention and treatment of restenosis of coronary artery cardle operation,” Modern Medicine & Health, vol. 20, p. 1858, 2004.
  62. X. B. Li, “Clinical observation and effect of TXA2, PGI2 on Tongmaiyuxin concentrated pill treating and preventing restenosis after PCI,” Guangming Journal of Chinese Medicine, vol. 24, pp. 1629–1630, 2009.
  63. Y. Li and J. H. Niu, “The preventive effects of on re-stricture viscosity reduction mixture after percutaneous intracavitary plastic operation,” Journal of Shandong Medical College, vol. 30, pp. 229–232, 2008.
  64. J. Liu, X. H. Fu, W. L. Wu et al., “Influence of tripterygium polyglycosides on restenosis after intracoronary stenting,” Journal of Chinese Integrative Medicine, vol. 22, pp. 894–898, 2002.
  65. Y. J. Liu, G. Y. Sun, Z. Y. Liu, S. Z. Zhang, and S. L. Liang, “Clinical effects of tetramethyl pyrazine on preventing restenosis after percutaneous coronary intervention,” Chinese Journal of Cardiovascular Medicine, vol. 9, pp. 90–92, 2004.
  66. S. B. Liu, J. S. Li, and Y. Zhang, “Clinical experience about Chinese herbal medicine with effects of replenishing qi and activating blood preventing on restenosis after percutaneous transluminal coronary angioplasty,” Chinese Archives of Traditional Chinese Medicine, vol. 25, pp. 2556–2558, 2007.
  67. X. Y. Lu, D. Z. Shi, and H. Xu, “Clinical study on effect of xiongshao capsule on restenosis after percutaneous coronary intervention,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 26, no. 1, pp. 13–17, 2006. View at Scopus
  68. S. H. Ma, “Clinical observation of Guanmai zhaitong decoction for prevention and treatment of restenosis of coronary artery after cradle operation,” Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 7, p. 1389, 2009.
  69. J. H. Niu, D. Li, S. Xi, and X. Y. Liu, “Clinical study on xueyutong mixture preventing coronary restenosis after plastic and cytoskeletal operation in coronary heart disease,” Shandong Journal of Traditional Chinese Medicine, vol. 22, pp. 395–397, 2003.
  70. J. Y. Qi, M. Z. Zhang, J. Li, B. J. Chen, and K. L. Chen, “Effect of Tongguan capsule on restenosis and blood rheology after pecutaneous coronary intervention,” Chinese Archives of Traditional Chinese Medicine, vol. 21, pp. 882–883, 2003.
  71. Z. Q. Qiao, M. Z. Zhang, X. W. Zhang, S. Li, and K. L. Chen, “A randomized double-blinded placebo-controlled clinical study of Tongguan capsule improving life quality of patients after PCI,” Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 4, pp. 4–5, 2006.
  72. D. Z. Shi, J. Li, X. C. Ma et al., “Clinical observation on prevention of restenosis in cases with coronary heart disease after percutaneous transluminal coronary angioplasty with concentrated Xuefu Zhuyu Pill,” Journal of Traditional Chinese Medicine, vol. 38, pp. 27–29, 1997.
  73. H. Y. Wang, T. N. Fang, and F. Wu, “Effect of therapy of strengthening qi and activating blood on cardiac function in patients with coronary heart disease after percutaneous coronary intervention,” Journal of New Chinese Medicine, vol. 41, pp. 39–41, 2009.
  74. Q. Wang, X. R. Xu, Z. Y. Wang et al., “Clinical observation of Shanshen tongmai composition treating the angina of patients after stenting intervention,” Chinese Journal of Information on Traditional Chinese Medicine, vol. 13, pp. 68–69, 2006.
  75. X. Wang, Z. X. Lin, J. B. Ge et al., “Preliminary observation on application of shuxinyin after coronary artery stenting,” Journal of Chinese Integrative Medicine, vol. 22, pp. 809–812, 2002.
  76. X. Wang, L. R. Yun, Z. X. Lin, and J. B. Ge, “Effect of buxinyin-chaifang on the inflammatory factors in patients after coronary artery stenting,” Chinese Journal of Gerontology, vol. 23, pp. 144–146, 2003.
  77. X. T. Wang and Y. H. Gao, “Influence of yixin capsule on restenosis after intracoronary stenting,” Chinese Journal of Cardiovascular Review, vol. 2, pp. 860–862, 2004.
  78. Z. H. Wang, J. Zhang, and Y. Xing, “Effect of Kudiezi injection on stent thrombosis and matrix metalloproteinase in patients with PCI,” Journal of Jilin University Medicine Edition, vol. 36, no. 2, pp. 377–380, 2010. View at Scopus
  79. H. B. Xiao, D. D. Zhang, and J. Gu, “Effects of tongxinluo on C-reactive protein and clinical prognosis in patients after coronary stenting,” Journal of Interventional Radiology, vol. 16, no. 8, pp. 520–522, 2007. View at Scopus
  80. H. Xu, D. Shi, and K. Chen, “Clinical effect of Xiongshao capsule on preventing restenosis post-PTCA or/and stenting,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 20, no. 7, pp. 494–497, 2000. View at Scopus
  81. K. J. Chen, D. Z. Shi, H. Xu et al., “XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China. Chin Med J,2006;119:6-13. *Xu H, Lu XY, Chen KJ, et al. Study on correlation of blood-stasis syndrome and its accompanied syndromes with pathological changes showed in coronary angiography and restenosis after percutaneous coronary intervention,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 27, no. 8, pp. 13–2007, One trial reported in two publications each describing different outcome measures.
  82. F. M. Yao, L. Liu, and G. Y. Ge, “Clinical study of Tong xin lou capsule in preventing restenosis in patients with coronary heart disease,” Chinese Journal of Difficult and Complicated Cases, vol. 5, pp. 191–192, 2006.
  83. Z. G. Yi, J. S. He, Q. Wang, L. Q. Shu, and L. Q. Yang, “Clinical efficacy of self-prepared guantong decotion for prevention PTCA and stenosis after coronary stenting,” Journal of Changchun University of Traditional Chinese Medicine, vol. 8, pp. 33–35, 2005.
  84. B. Yu, K. Chen, and J. Mao, “Clinical study on effect of concentrated xuefu zhuyu pill on restenosis of 43 cases coronary heart disease after intracoronary stenting,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 18, no. 10, pp. 585–589, 1998. View at Scopus
  85. Z. A. Yu and S. Y. Yu, “Preliminary observation on oral danshen pian after coronary artery stenting,” Shanghai Medical Journal, vol. 29, pp. 280–282, 2006.
  86. Z. H. Zheng, M. S. Wu, T. W. Liu, P. Li, L. G. Zhu, and D. J. Zhu, “The effect of probucol and fu fang dan shen drops alone and incombination on restenosis after intracoronary stenting,” Journal of Guangxi Medical University, vol. 21, pp. 809–814, 2004.
  87. Z. M. Zhang, Y. X. Gao, H. L. Liu, Y. Q. Yuan, and L. Yu, “Wentongjian in prevented coronary restenosis of percutaneous coronary intervention,” Chinese Journal of Arteriosclerosis, vol. 14, pp. 610–612, 2006.
  88. W. M. Zhang, W. Zhang, and J. Zheng, “Clinical study of Shenmai gualou shixiao power treating recurrence angina after coronary in-stent,” Journal of Traditional Chinese Medicine University of Hunan, vol. 27, pp. 49–51, 2007.
  89. H. Y. Zhao, W. H. Wang, J. M. Lang et al., “The effect mechanism of shenqi decoction on restenosis after implantation of stents in coronary artery disease,” Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 7, pp. 382–384, 2009.
  90. J. Zhou and J. T. Guo, “Clinical study of tongxinluo on preventing re-stenosis of stents in CHD,” Heibei Medicine, vol. 13, pp. 1187–1190, 2007.
  91. L. Y. Zhu, L. Yan, and Z. W. Yang, “Clinical study of Danhong tongmai capsule preventing restenosis in stent and forming of late coronary thrombosis,” Chinese Journal of Basic Medicine in Traditional Chinese Medicine, vol. 15, pp. 682–683, 2009.
  92. X. Y. Zheng, Guiding Principle of Clinical Research on New Drugs of Traditional Chinese Medicine, Chinese Medicine Science and Technology Press, Beijing, China, 2002.
  93. R. E. Kuntz and D. S. Baim, “Defining coronary restenosis: newer clinical and angiographic paradigms,” Circulation, vol. 88, no. 3, pp. 1310–1323, 1993. View at Scopus
  94. J. Gilbert, J. Raboud, and B. Zinman, “Meta-Analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting,” Diabetes Care, vol. 27, no. 4, pp. 990–994, 2004. View at Publisher · View at Google Scholar · View at Scopus
  95. L. Martínez-Elbal, J. M. Ruiz-Nodar, J. Zueco et al., “Direct coronary stenting versus stenting with balloon pre-dilation: immediate and follow-up results of a multicentre, prospective, randomized study. The DISCO trial,” European Heart Journal, vol. 23, no. 8, pp. 633–640, 2002. View at Publisher · View at Google Scholar · View at Scopus